Patents Assigned to GlaxoSmithKline Biological S.A.
-
Publication number: 20200123571Abstract: The present invention relates to nucleic acid constructs capable of encoding antigenic peptides or polypeptides derived from multiple Human Papilloma Virus (HPV) early proteins, and to immunogenic compositions comprising such nucleic acid constructs and a pharmaceutically acceptable carrier. Such nucleic acid constructs and immunogenic compositions are useful in the treatment of persistent HPV infection and low-grade HPV lesions, particularly infections and lesions of human anogenital epithelial tissue, such as cervical epithelia.Type: ApplicationFiled: September 27, 2017Publication date: April 23, 2020Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Wivine BURNY, Cindy CASTADO, Sandra GIANNINI, Julien Thierry MASSAUX
-
Publication number: 20200113830Abstract: Nucleic acid immunisation is achieved by delivering RNA encapsulated within a PEGylated liposome. The RNA encodes an immunogen of interest. The PEG has an average molecular mass above 3 kDa but less than 11 kDa. Thus the invention provides a liposome having a lipid bilayer encapsulating an aqueous core, wherein: (i) the lipid bilayer comprises at least one lipid which includes a polyethylene glycol moiety, such that polyethylene glycol is present on the liposome's exterior, wherein the average molecular mass of the polyethylene glycol is above 3 kDa but less than 11 kDa; and (ii) the aqueous core includes a RNA which encodes an immunogen.Type: ApplicationFiled: December 16, 2019Publication date: April 16, 2020Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Andrew GEALL, Ayush VERMA
-
Publication number: 20200102405Abstract: A method of lipopolysaccharide (LPS) extraction from gram negative bacterial cells is provided, said method comprising a step of extracting LPS from the gram negative bacterial cell in a LPS extraction solution comprising a salt, water, an alcohol, and a further organic solvent. Compositions and uses of the extracted LPS are also provided.Type: ApplicationFiled: December 21, 2016Publication date: April 2, 2020Applicant: GLAXOSMITHKLINE BIOLOGICALS, S.A.Inventors: Jeffrey A. KERN, Chad FARRENBURG
-
Patent number: 10583185Abstract: Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates of E. coli polysaccharide antigens O25B, O1A, O2, and O6A covalently bound to a detoxified exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein as vaccines for the prevention of invasive ExPEC disease caused by ExPEC serotypes O1A, O2, O6A and O25B.Type: GrantFiled: August 24, 2016Date of Patent: March 10, 2020Assignees: GlaxoSmithKline Biological S.A., Janssen Pharmaceuticals, Inc.Inventors: Jan Theunis Poolman, Bert Jacquemyn, Darren Robert Abbanat, Patricia Ibarra Yon, Peter Wilhelmus Maria Hermans, Michael Thomas Kowarik, Michael Lukas Wetter, Stefan Jochen Kemmler, Micha Andres Häuptle, Veronica Gambillara Fonck, Manuela Mally
-
Publication number: 20200061186Abstract: The present invention provides compositions, methods and processes for the maturation of submicron liposome compositions comprising a lipid, a sterol, and a saponin.Type: ApplicationFiled: December 5, 2017Publication date: February 27, 2020Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Philippe CARA, Veronique Monique Roberte HENDERICKX, Vinciane Martha DE CUPERE, Carine Berthe Ghislaine DE KESEL
-
Publication number: 20200023051Abstract: The present invention relates to the field of native outer membrane vesicles (nOMVs), particularly nOMVs having increased levels of lipoproteins on their surface and use of same in immunogenic compositions.Type: ApplicationFiled: June 29, 2017Publication date: January 23, 2020Applicant: GLAXOSMITHKLINE BIOLOGICALS, S.A.Inventors: Beatrice RICCHETTI, Isabel DELANY
-
Patent number: 10532067Abstract: RNA encoding an immunogen is co-delivered to non-immune cells at the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g. by a single injection.Type: GrantFiled: October 5, 2017Date of Patent: January 14, 2020Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Walter Mandl
-
Publication number: 20190365930Abstract: The present invention relates to the formulation of adenoviral vectors in sorbitol containing compositions in combination with a further amorphous sugar, its formulation as well as a method for obtaining a dried composition.Type: ApplicationFiled: January 25, 2018Publication date: December 5, 2019Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Erwan BOURLES, Olivier DESPAS, Delphine GUILLAUME, Frederic MATHOT, Mathieu VASSELLE
-
Patent number: 10485761Abstract: In one aspect, the present invention provides sterile microparticle compositions comprising biodegradable microparticles, which comprise at least one biodegradable polymer. In other aspects, the present invention provides methods of making and using such compositions as well as articles of manufacture and kits containing the same.Type: GrantFiled: May 16, 2018Date of Patent: November 26, 2019Assignee: GLAXOSMITHKLINE BIOLOGICALS, S.A.Inventors: Derek O'Hagan, Manmohan Singh, Siddhartha Jain, Padma Malyala
-
Publication number: 20190345205Abstract: Compounds useful as components of immunogenic compositions for the induction of an immunogenic response in a subject against viral infection, methods for their use in treatment, and processes for their manufacture are provided herein. The compounds comprise a nucleic acid construct comprising a sequence which encodes a Zika virus antigen.Type: ApplicationFiled: November 15, 2017Publication date: November 14, 2019Applicants: GLAXOSMITHKLINE BIOLOGICALS, S.A., The United States of America, as Represented by the Department of Health and Human ServicesInventors: Kimberly DOWD, Barney S. GRAHAM, Sung-Youl KO, Wing-Pui KONG, John MASCOLA, Theodore PIERSON, Mayuri SHARMA, Dong Yu
-
Publication number: 20190322708Abstract: Methods for the production of a bacterial toxin such as diphtheria toxin, and methods for producing conjugates of a bacterial toxins, are provided.Type: ApplicationFiled: July 11, 2019Publication date: October 24, 2019Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Normand Blais, Philippe Marc Helene Dehottay, Marianne Dewerchin, Philippe Goffin, Denis Martin
-
Publication number: 20190300905Abstract: The present invention relates to isolated polynucleotide and polypeptide sequences derived from novel chimpanzee adenovirus ChAd157, as well as to recombinant polynucleotides, vectors, adenoviruses, cells and compositions comprising said polynucleotide and polypeptide sequences.Type: ApplicationFiled: December 7, 2017Publication date: October 3, 2019Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Virginia AMMENDOLA, Stefania CAPONE, Stefano COLLOCA, Antonella FOLGORI, Rosella MERONE
-
Publication number: 20190282684Abstract: A method for immunizing a subject in need thereof against Neisseria gonorrhoeae by administering an immunogenic composition comprising meningococcal outer membrane vesicles (OMVs).Type: ApplicationFiled: September 1, 2017Publication date: September 19, 2019Applicant: GLAXOSMITHKLINE BIOLOGICALS, S.A.Inventors: Mariagrazia PIZZA, Steven B. BLACK
-
Publication number: 20190282685Abstract: The invention provides Chlamydia antigens for use in the treatment, prevention and/or diagnosis of Chlamydia infection. In particular, the invention provides antigens CT733, CTI 53, CT601, CT279, CT443, CT372, CT456, CT381, CT255, CT341, CT716, CT745, CT387, CT812, CT869, CT166, CT175, CT163, CT214, CT721, CT127, CT043, CT823 and/or CT600 from C. trachomatis for the treatment, prevention or diagnosis of Chlamydia infection.Type: ApplicationFiled: January 29, 2019Publication date: September 19, 2019Applicant: GLAXOSMITHKLINE BIOLOGICALS, S.A.Inventors: Guido GRANDI, Renata Maria GRIFANTINI, Oretta FINCO
-
Publication number: 20190282682Abstract: Provided herein are host cells capable of producing hybrid oligosaccharides and polysaccharides, wherein said hybrid oligosaccharides and polysaccharides do not comprise a hexose at the reducing end of their first repeat unit. Also provided herein are hybrid oligosaccharides or polysaccharides and bioconjugates which can be produced by the host cells described herein, wherein said bioconjugates comprise a carrier protein linked to a hybrid oligosaccharide or polysaccharide that does not comprise a hexose at the reducing end of its first repeat unit.Type: ApplicationFiled: April 16, 2019Publication date: September 19, 2019Applicant: GLAXOSMITHKLINE BIOLOGICALS, S.A.Inventor: Amirreza FARIDMOAYER
-
Patent number: 10414802Abstract: This invention relates to cytomegalovirus (CMV) proteins suitable for vaccine uses. Provided herein are mammalian host cells, in particular CHO cells, in which the sequence(s) encoding CMV proteins gH, gL, pUL128, pUL130, pUL131 (or a complex-forming fragment thereof) are stably integrated into the genome.Type: GrantFiled: October 29, 2015Date of Patent: September 17, 2019Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Andrea Carfi, Claudio Ciferri, Irmgard Hofmann, Holger Laux, Anders Lilja, Yingxia Wen
-
Publication number: 20190275141Abstract: The invention relates to an immunization regimen whereby an infant is protected against respiratory syncytial virus (RSV) through administration of a first anti-RSV immune response inducing composition to his or her mother during pregnancy, followed by administration of a second anti-RSV immune response inducing composition to the infant after birth.Type: ApplicationFiled: May 28, 2019Publication date: September 12, 2019Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventor: Philip DORMITZER
-
Publication number: 20190276498Abstract: The disclosure provides modified cytomegalovirus (CMV) gL proteins and complexes comprising gL proteins. The modified gL proteins remain intact and are able to form complexes with other CMV proteins.Type: ApplicationFiled: November 15, 2018Publication date: September 12, 2019Applicant: GLAXOSMITHKLINE BIOLOGICALS, S.A.Inventors: Andrea CARFI, Claudio CIFERRI, Yi XING
-
Patent number: 10406101Abstract: The present invention provides processes for the production of a submicron oil in water emulsion comprising the steps: a. preparing a submicron oil in water emulsion; b. pre-filtering the oil in water emulsion; c. filtering the oil in water emulsion filtered according to step b) through a sterile grade filter; d. filtering the oil in water emulsion filtered according to step c) through a filter separate to that of step b) or step c); and e. filtering the oil in water emulsion filtered according to step d) through a sterile grade filter separate to that of steps b), c) and/or d).Type: GrantFiled: April 6, 2015Date of Patent: September 10, 2019Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Vinciane De Cupere, Vincent Mancuso
-
Patent number: 10398771Abstract: A process for producing a split influenza virus preparation or subunit influenza preparation comprising the steps of: (i) providing a whole virus preparation; (ii) splitting the whole virus preparation in the presence of a first detergent; (iii) adding t-octylphenoxypolyethoxyethanol (TRITON X-100™) to the resulting split virus preparation; and (iv) filtering the split virus preparation.Type: GrantFiled: March 23, 2017Date of Patent: September 3, 2019Assignees: GLAXOSMITHKLINE BIOLOGICAL S.A., GLAXOSMITHKLINE BIOLOGICALS, NIEDERLASSUNG DER SMITHKLINE BEECHAM PHARMA GMBH & CO KGInventors: Erik Jozef D'Hondt, Hans Bernd Engelmann